Unfractionated heparin, low molecular weight heparins, and pentasaccharide: Basic mechanism of actions, pharmacology, and clinical use

被引:57
作者
Bick, RL
Frenkel, EP
Walenga, J
Fareed, J
Hoppensteadt, DA
机构
[1] Dallas Thrombosis Hemostasis & Vasc Med Clin Ctr, Dallas, TX 75231 USA
[2] Univ Texas, SW Med Sch, Dept Med, Dallas, TX 75235 USA
[3] Univ Texas, SW Med Sch, Dept Pathol, Dallas, TX 75235 USA
[4] Univ Texas, SW Med Sch, Dept Med, Dallas, TX 75235 USA
[5] Univ Texas, SW Med Sch, Dept Radiol, Dallas, TX 75235 USA
[6] Loyola Univ, Dept Pathol & Pharmacol, Maywood, IL 60153 USA
[7] Loyola Univ, Dept Cardiovasc Surg, Maywood, IL 60153 USA
关键词
D O I
10.1016/j.hoc.2004.09.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
During the past decade, a large number of new anticoagulant and antithrombotic drugs have been developed. These agents represent a wide variety of substances that are derived using natural sources biotechnology-based methods, and synthetic approaches. Because of the structural and molecular characteristics, these agents exhibit physicochemical and functional diversities. Thus, each of these classes of drugs controls thrombogenesis by way of distinct mechanisms. The main classes of these new drugs include peptides, peptidomimetics, heparinomimetics, and recombinant proteins. Despite these significant developments, heparin and heparin-derived drugs have continued to play a major role in the management of thrombotic and cardiovascular disorders.
引用
收藏
页码:1 / +
页数:52
相关论文
共 119 条
[31]  
FAREED J, 1986, HAEMOSTASIS, V16, P123
[32]   Pharmacodynamic and pharmacokinetic properties of enoxaparin - Implications for clinical practice [J].
Fareed, J ;
Hoppensteadt, D ;
Walenga, J ;
Iqbal, O ;
Ma, Q ;
Jeske, W ;
Sheikh, T .
CLINICAL PHARMACOKINETICS, 2003, 42 (12) :1043-1057
[33]  
Fareed J, 1999, SEMIN THROMB HEMOST, V25, P51
[34]   STUDIES ON THE ANTITHROMBOTIC EFFECTS AND PHARMACOKINETICS OF HEPARIN FRACTIONS AND FRAGMENTS [J].
FAREED, J ;
WALENGA, JM ;
WILLIAMSON, K ;
EMANUELE, RM ;
KUMAR, A ;
HOPPENSTEADT, DA .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1985, 11 (01) :56-74
[35]  
Fareed J, 1999, SEMIN THROMB HEMOST, V25, P3
[36]  
FAREED J, 1988, HAEMOSTASIS, V18, P3
[37]  
*FDA, 2000, LOV EN SOD INJ MAY 3
[38]  
FIDLAR E, 1948, J LAB CLIN MED, V33, P1410
[39]  
Frydman A, 1996, HAEMOSTASIS, V26, P24
[40]   THE ANTITHROMBOTIC ACTIVITY AND PHARMACOKINETICS OF ENOXAPARINE, A LOW-MOLECULAR WEIGHT HEPARIN, IN HUMANS GIVEN SINGLE SUBCUTANEOUS DOSES OF 20 TO 80 MG [J].
FRYDMAN, AM ;
BARA, L ;
LEROUX, Y ;
WOLER, M ;
CHAULIAC, F ;
SAMAMA, MM .
JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 28 (07) :609-618